BACKGROUND: Mesenchymal stromal cells (MSC) have shown diverse therapeutic potential. While characterization of human and mouse MSC has seen significant advances, rat bone marrow-derived MSC (rBM-MSC) remain under-characterized. We detail the isolation, expansion, differentiation, and detailed immunocharacterization of rBM-MSC. METHODS: Rat MSC were isolated and expanded in multipotent adult progenitor cell (MAPC) media, and cell-surface marker expression through 10 passages was used to characterize the population and multipotency was confirmed via differentiation. RESULTS: By passage 3, rBM-MSC were found to be CD11b-, CD45-, CD29+, CD49e+, CD73+, CD90+, CD105+ and Stro-1+, without the use of cell sorting. Media selection was responsible for the isolation of a nearly homogeneous population of rBM-MSC. The rBM-MSC immunophenotype changed by passage 10, showing decreases in CD73, CD105 and Stro-1 expression. DISCUSSION: Detailed characterization of cell populations facilitates accurate and reproducible cell therapy investigation. Given the expanding body of research involving rBM-MSC, these results advance our ability to compare rBM-MSC populations.
BACKGROUND: Mesenchymal stromal cells (MSC) have shown diverse therapeutic potential. While characterization of human and mouse MSC has seen significant advances, rat bone marrow-derived MSC (rBM-MSC) remain under-characterized. We detail the isolation, expansion, differentiation, and detailed immunocharacterization of rBM-MSC. METHODS:Rat MSC were isolated and expanded in multipotent adult progenitor cell (MAPC) media, and cell-surface marker expression through 10 passages was used to characterize the population and multipotency was confirmed via differentiation. RESULTS: By passage 3, rBM-MSC were found to be CD11b-, CD45-, CD29+, CD49e+, CD73+, CD90+, CD105+ and Stro-1+, without the use of cell sorting. Media selection was responsible for the isolation of a nearly homogeneous population of rBM-MSC. The rBM-MSC immunophenotype changed by passage 10, showing decreases in CD73, CD105 and Stro-1 expression. DISCUSSION: Detailed characterization of cell populations facilitates accurate and reproducible cell therapy investigation. Given the expanding body of research involving rBM-MSC, these results advance our ability to compare rBM-MSC populations.
Authors: Uwe M Fischer; Matthew T Harting; Fernando Jimenez; Werner O Monzon-Posadas; Hasen Xue; Sean I Savitz; Glen A Laine; Charles S Cox Journal: Stem Cells Dev Date: 2009-06 Impact factor: 3.272
Authors: Peter A Walker; Fernando Jimenez; Michael H Gerber; Kevin R Aroom; Shinil K Shah; Matthew T Harting; Brijesh S Gill; Sean I Savitz; Charles S Cox Journal: Tissue Eng Part C Methods Date: 2010-10 Impact factor: 3.056
Authors: A P Bonartsev; I I Zharkova; V V Voinova; E S Kuznetsova; V A Zhuikov; T K Makhina; V L Myshkina; D M Potashnikova; D V Chesnokova; D D Khaydapova; G A Bonartseva; K V Shaitan Journal: 3 Biotech Date: 2018-07-18 Impact factor: 2.406
Authors: Peter A Walker; Matthew T Harting; Fernando Jimenez; Shinil K Shah; Shibani Pati; Pramod K Dash; Charles S Cox Journal: Stem Cells Dev Date: 2010-06 Impact factor: 3.272
Authors: Miranda Brenneman; Sushil Sharma; Matthew Harting; Roger Strong; Charles S Cox; Jarek Aronowski; James C Grotta; Sean I Savitz Journal: J Cereb Blood Flow Metab Date: 2009-09-23 Impact factor: 6.200